Phase 1b/2a Evaluation of the Safety and Tolerability of SYN-004 in Adult Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Recipients
Latest Information Update: 25 Apr 2025
At a glance
- Drugs Ribaxamase (Primary) ; Cefepime; Meropenem; Piperacillin/tazobactam
- Indications Graft-versus-host disease
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Theriva Biologics
Most Recent Events
- 10 Apr 2025 According to Theriva Biologics media release, data from this study will be featured in an ePoster Flash Session oral presentation at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global), taking place in Vienna, Austria from April 11-15, 2025.
- 19 Nov 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 19 Nov 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.